Korelasi Kadar Limfosit dengan Nilai P/F Rasio pada Pasien COVID-19 Derajat Berat

Yazid Bustomi, Reza Widianto Sudjud, Ardi Zulfariansyah

Abstract


Virus SARS-CoV-2 menyebabkan penyakit pernapasan akut yang disebut COVID-19 dan menyebabkan pandemi global. Limfopenia adalah salah satu kelainan laboratorium utama pada pasien COVID-19 derajat berat yang mengalami ARDS dengan penurunan P/F rasio. Penelitian ini bertujuan menganalisis korelasi kadar limfosit dengan P/F rasio pada pasien COVID-19 derajat berat. Penelitian dilakukan di ICU COVID-19 RSUP Dr. Hasan Sadikin Bandung dengan menelusuri rekam medik pada periode Januari hingga Juli 2021. Penelitian ini adalah penelitian observasional analitik dengan rancangan kohort retrospektif menggunakan model pendekatan waktu secara longitudinal atau time period approach. Penilaian dilakukan pada saat subjek dirawat pada hari ke-1, 3, dan ke-7 di ICU COVID-19 RSUP Dr. Hasan Sadikin Bandung. Uji normalitas data numerik menggunakan uji Shapiro Wilk didapatkan hasil data berdistribusi tidak normal. Selanjutnya, pada penelitian ini dilakukan uji korelasi Spearman. Tidak terdapat korelasi antara kadar limfosit dan P/F rasio pada pasien COVID-19 derajat berat (p=0,125; R=0,126). Didapatkan sebagian besar pasien COVID-19 derajat berat memiliki kadar limfosit <1.000 uL dan P/F rasio <150 mmHg (p<0,05). Simpulan, tidak terdapat korelasi antara kadar limfosit dan P/F rasio pada COVID-19 derajat berat, walaupun pada sebagian besar kasus COVID-19 derajat berat didapatkan penurunan limfosit dan P/F rasio.

 

Keywords


COVID-19; Limfosit; P/F rasio

Full Text:

PDF

References


  1. Sugihantono A, Burhan E, Samuedro E, Rinawati W, Ginanjar E, Soeroto AY, dkk. Pedoman pencegahan dan pengendalian corona virus disease 2019 (COVID-19). Kementrian Kesehatan Republik Indonesia. Juli 2020;5:19–21. [Internet] 2021 [diunduh 20 Agustus 2021]. Tersedia dari: https://covid19.go.id/Juli/REV-05_Pedoman_P2_COVID 19.pdf.
  2. Fatoni AZ, Rakhmatullah R. Acute respiratory distress syndrome (ARDS) pada pneumonia COVID-19. J Anaesth Pain. 2021;2(1):11–24.
  3. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:1–7.
  4. Liu J, LI H, Luo M, Liu J, Wu L, Lin X, dkk. Lymphopenia predicted illness severity and recovery in patients with COVID-19: A single-center, retrospective study. PLoS One. 2020;15(11):1–15.
  5. Zou Z, Chen R, Ren D, Yu BJ, Feng YW, Wu M. Persistent lymphopenia after diagnosis of COVID- 19 predicts acute respiratory distress syndrome: a retrospective cohort study. Research Square. 2019.
  6. Tan L, Wang Q, Zhang D, Ding J, Tang YQ, Wang Q, dkk. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(3):16–8.
  7. Zou Z, Chen R, Ren D, Yu BJ, Feng YW, Wu M. Persistent lymphopenia after diagnosis of COVID- 19 predicts acute respiratory distress syndrome : A retrospective cohort study. Research Square. 2019.
  8. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J Intensive Care. 2020;8(1):1–10.
  9. Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical profile of elderly patients with COVID-19 hospitalised in Indonesia’s National General Hospital. Acta Med Indones. 2020;52(3):199–205.
  10. Mahayasa DP, Putri AK. Maskulinitas dan Pandemi COVID-19: Studi kasus Pakistan. Jurnal Hubungan Internasional. 2020 Nov 28;13(2):163–84.
  11. Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical profile of elderly patients with COVID-19 hospitalised in Indonesia’s National General Hospital. Acta Med Indones. 2020;52(3):199–205.
  12. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, dkk. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. Lancet Reg Heal West Pac. 2021;9:100108.
  13. Gao Y dong, Ding M, Dong X, Zhang JJ, Azkur AH, Azkur D, dkk. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–55.
  14. De Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD, Rodacki M, dkk. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12(1):1–12.
  15. Van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, dkk. COVID-19: immunopathology, patho physiological mechanisms, and treatment options. J Pathol. 2021;254(4):307–31.
  16. Swenson KE, Swenson ER. S Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin. 2021;37(4):749–76.
  17. Hussain M, Syed SK, Fatima M, Shaukat S, Alqahtani AM, Alqahtani T, dkk. Acute respiratory distress syndrome and COVID-19: a literature review. J Inflamm Res. 2021;14: 7225–42.
  18. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, dkk. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus isease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.
  19. Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol. 2020;11:1–16.




DOI: https://doi.org/10.15851/jap.v11n1.2793

Article Metrics

Abstract view : 261 times
PDF - 310 times


 

This Journal indexed by

                   

           


 
Creative Commons License
JAP is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 



View My Stats